CalciMedica, Inc. filings document regulatory disclosures for a clinical-stage biopharmaceutical company developing CRAC channel inhibition therapies. The company’s Form 8-K reports cover results of operations and financial condition, clinical program events involving Auxora, and related updates for inflammatory and immunologic disease programs.
The filing record also includes capital-structure and governance disclosures, including Nasdaq continued-listing compliance matters, at-the-market offering documentation, shareholder voting matters, and the company’s common stock registration on The Nasdaq Capital Market under the symbol CALC.
CalciMedica, Inc. director Evgeny Zaytsev received a grant of stock options covering 20,000 shares of common stock. The options have an exercise price of $0.9654 per share and expire on July 1, 2036. This is a compensation-related award, not an open-market trade. Following the grant, he holds options on 20,000 shares directly. According to the vesting terms, 1/36 of the options vest in equal monthly installments over three years from the grant date.
CalciMedica, Inc. director Evgeny Zaytsev filed an initial ownership report showing indirect holdings through Bering Partners II, L.P. Bering II holds 2,113,513 shares of common stock and a warrant for 130,651 underlying common shares at an exercise price of $7.15 per share, expiring on December 31, 2026. The warrant is subject to a beneficial ownership cap that was increased from 4.99% to 19.99% effective after notice given on July 2, 2026, limiting how much of CalciMedica’s stock can be held upon exercise.
CalciMedica, Inc. reported changes to its board of directors. On July 2, 2026, the board expanded from seven to eight members and appointed Evgeny Zaytsev, M.D., Ph.D. as a Class I director, with a term running until the 2027 annual meeting of stockholders.
Under the company’s non-employee director compensation policy, he will receive a pro-rated annual cash retainer of $40,000 and an option to purchase 20,000 shares of common stock, vesting monthly over three years from July 2, 2026, subject to continuous service. CalciMedica also disclosed that director Fred Middleton intends to retire effective at the 2026 annual meeting, at which time the board size will return to seven, and that his retirement does not stem from any disagreement with the company.
Bering Partners II and affiliates filed a Schedule 13D reporting beneficial ownership of 2,113,513 shares of CalciMedica common stock, representing 6.9% of the outstanding shares. The stake is held through Bering Partners II, L.P., a venture capital investment entity.
The position was built through shares received in CalciMedica’s merger with Graybug Vision, prior private placements, open-market purchases, an underwritten offering, and a June 25, 2026 private placement in which Bering II bought 1,450,267 units at $0.8033 per unit. Bering II also holds warrants, including a remaining warrant at an exercise price of $7.15 and rights to receive Series A and Series B warrants, all subject to ownership caps generally not exceeding 19.99%.
CalciMedica investors Eric Roberts and A. Rachel Leheny have increased their stakes and updated their ownership disclosures in an Amendment No. 4 to Schedule 13D. As of a total of 30,736,401 common shares outstanding on June 25, 2026, Roberts beneficially owns 1,965,916 shares, or 6.4% of the class, and Leheny beneficially owns 1,926,347 shares, or 6.3%.
The filing details numerous open-market purchases of CalciMedica common stock by both individuals during mid-2025, along with an option exercise by Roberts. It also notes that on June 25, 2026, Roberts and Leheny each acquired 186,729 Units at $0.8033 per Unit in a public offering, with each Unit consisting of one share and one pre-funded warrant, funded with their personal capital.
CalciMedica, Inc. reported that an investment fund affiliated with director and 10% owner Fred A. Middleton increased its stake. On June 25, 2026, Sanderling Venture Partners VI Co-Investment Fund, L.P. acquired 248,972 shares of common stock at $0.8033 per share. The shares were purchased directly from CalciMedica under a Securities Purchase Agreement dated June 23, 2026, which was approved by an independent committee of the board. Following this transaction, that fund holds 1,063,272 shares of CalciMedica common stock. Middleton also reports additional direct and indirect holdings, including 36,514 shares held directly and various positions through Sanderling and Golden Triangle entities, while disclaiming beneficial ownership beyond his pecuniary interest.
CalciMedica, Inc. Chief Medical Officer Sudarshan Hebbar acquired 124,486 shares of Common Stock on June 25, 2026 at an indicated price of $0.8033 per share. This brings his direct holdings to 186,025 shares. The shares were obtained from the company under a Securities Purchase Agreement dated June 23, 2026, which was approved by an independent committee of the board of directors.
CalciMedica director Robert N. Wilson acquired 1,182,621 shares of Common Stock at $0.8033 per share. After this transaction, he directly holds 1,604,650 shares. The shares were obtained from the company under a Securities Purchase Agreement dated June 23, 2026, which was approved by an independent board committee and closed on June 25, 2026.
CalciMedica, Inc. director and chief business officer Eric W. Roberts reported a stock award of common shares. He acquired 186,729 shares of common stock at $0.8033 per share in a grant or award transaction. The securities were issued under a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026, which was approved by an independent committee of the board of directors.
Following this grant, Roberts directly holds 366,435 common shares. He also has indirect holdings through several entities and retirement accounts, including 316,109 shares held by Valence Investments SPV VI, LLC, 356,989 shares held by Valence Investments SPV IV, LLC, and additional positions in IRA and Roth IRA accounts.
CalciMedica, Inc. director, chief executive officer and 10% owner Rachel A. Leheny reported acquiring 186,729 shares of common stock at $0.8033 per share. The shares were obtained from the company under a Securities Purchase Agreement dated June 23, 2026 with a closing date of June 25, 2026, which was approved by an independent committee of the board. Following this transaction, she directly holds 317,655 common shares. She is also reported as indirectly holding 316,109 shares through Valence Investments SPV VI, LLC, 66,228 through Valence Investments SPV V, LLC, 356,989 through Valence Investments SPV IV, LLC, 3,500 through the Scheibler-Leheny Family Living Trust, and 1,000 through her spouse, while disclaiming beneficial ownership of the Valence entities’ holdings except to the extent of her pecuniary interest.